Business Standard

Analysts' corner

Ranbaxy Laboratories & Havells India

Read more on:    Ranbaxy Laboratories | Havells India
Related News


Reco price/date: Rs 552/September 3
Current/target price: Rs 568.55/Rs 450
After the launch of Actos, Ranbaxy has given 14 per cent absolute returns, outperforming the market and the healthcare index by three per cent. However, the downward earnings revisions show the initial euphoria during the launch was not sustained. Also, except Lipitor, stocks have given negative returns in a six-month period. The trade recorded in a month was reversed in a two-quarter timeframe. Though the launch of Actos removes the overhang of the result of forfeiting exclusivities, analysts believe the competitive dynamics of the product launch would be tougher than initially estimated. They say this could lead to a downward estimate revision, as seen earlier. Maintain 'Sell'.

Antique Stock Broking


Reco price/date: Rs 550/September 3
Current/target price: Rs 555.25/Rs 680
The Havells India stock underperformed the Sensex by 6.0 per cent during the past three months. It is now trading at 12.1 times the 2013-14 estimated price/earnings ratio, which analysts believe is an attractive valuation. Analysts see steady growth in a tough operating environment, a strong balance sheet, improving free cash generation and a potential rise in the dividend payout as strong stock price drivers. JP Morgan thinks the recent guidance cut for Sylvania margins is priced in, and recent forex trends have become favourable. This could help alleviate concern on a further downside to Sylvania's margins. JP Morgan has raised its FY14 estimated earnings per share five per cent. Upgrade to 'Overweight' from 'Neutral'.

JP Morgan

Read more on:   
|

Read More

Fund managers divided on high beta preference

Riding high on the crest of the reforms wave, the markets touched their highest closing levels since July 2011 during the week under review ...

Quick Links

 

Market News

Asset-light

Europe's 30 largest listed banks reduced their total assets by almost euro 2 trillion ($2.76 trillion) last year

P-note share in FII assets races ahead

At Rs 2.07 lakh crore, value of investments through P-notes hits a 3-year high

Iron ore production yet to pick up in Karnataka

One year after the Apex Court allowing opening of 115 mines in category A and B, the production has barely touched 20 million tonnes

Surat diamantaires' co-operative dream lies shattered

Company set up to source rough diamonds in abeyance

Five firms buying back shares worth Rs 6,000 cr this year

Cairn India's whopping Rs 5,725-cr buyback offer is the major among five programmes this year

Back to Top